Brand names: Prepidil
Prostaglandin Analog
Route: Vaginal
Contraindications
CONTRAINDICATIONS Endocervically administered PREPIDIL Gel is not recommended for the following: a. Patients in whom oxytocic drugs are generally contraindicated or where prolonged contractions of the uterus are considered inappropriate, such as: • cases with a history of cesarean section or major uterine surgery • cases in which cephalopelvic disproportion is present • cases in which there is a history of difficult labor and/or traumatic delivery • grand multiparae with six or more previous term pregnancies cases with non-vertex presentation • cases with hyperactive or hypertonic uterine patterns • cases of fetal distress where delivery is not imminent • in obstetric emergencies where the benefit-to-risk ratio for either the fetus or the mother favors surgical intervention b. Patients with hypersensitivity to prostaglandins or constituents of the gel (see WARNINGS and ADVERSE REACTIONS ). c. Patients with placenta previa or unexplained vaginal bleeding during this pregnancy. d. Patients for whom vaginal delivery is not indicated, such as vasa previa or active herpes genitalia.
Pregnancy & Breastfeeding
5. Pregnancy Teratogenic Effects Prostaglandin E2 produced an increase in skeletal anomalies in rats and rabbits. No effect would be expected clinically, when used as indicated, since PREPIDIL Gel is administered after the period of organogenesis. PREPIDIL Gel has been shown to be embryotoxic in rats and rabbits, and any dose that produces sustained increased uterine tone could put the embryo or fetus at risk. See statements under General Precautions .
1 interaction on record
Concomitant intravenous use is contraindicated as dinoprostone may augment the activity of oxytocic agents. Remove vaginal insert at least 30 minutes before administering an oxytocic agent.
Source: NLP:dinoprostone